RE:RE:RE:RE:somethings gotta give...
Longholder99 wrote: Underpromise and overdeliver I think is more the case in terms of Dr Mandels' carefully chosen words. Likely that some preliminary talks have happened but won't be released as actual info until RDW is back as CEO. We are 2mos out in my opinion from it all hitting the ground. 6 weeks maybe. Depending on what the deal is we could be looking at a serious SP jump as those who are waiting and watching now.....jump in. Just a guess.
I am in that underpromise & overdeliver camp. With that in mind, my interpretation of Dr. Mandel's statement, "the company plans to apply for FDA breakthrough drug designation in the first quarter of 2023 on the basis of the Phase 2 clinical study data collected to date" leads me to believe the deal/partnership timeline is probably more than 2 months out.
However, I prefer your timeline. When it comes to unpredictability in biotech, I always follow worst-case scenarios as presented. In my opinion, this represents the most realistic (& sanity-conserving) approach to investing in this sector. First qtr of 2023 means to me an end of March app submission, which would hence lead to a BTD decision near end of May (worst case). With BTD in hand, more serious/fruitful partnership negotiations can then take place. If all unfolds according to my predictions, I see a partnership deal happening no earlier than fall of this year, which fits Dr. Mandel's conservative timeline estimation "to commence partnering talks with large pharmaceutical companies in 2023 / 2024 to commercialize the technology for BCG-unresponsive NMIBC CIS."
However, I much prefer your timeline...good luck.